Crizotinib, a tyrosine kinase inhibitor, shows efficacy in the treatment of ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC) and refractory inflammatory myofibroblastic tumors (IMTs) with ALK mutations. Here, ALK is linked to inflammatory myofibroblastic tumor.